Exact Sciences stock jumps 12% after UnitedHealth issues positive coverage for Cologuard

Madison, Wis.-based Exact Sciences saw shares increase 12 percent after Minnetonka, Minn.-based UnitedHealthcare said it would cover the company's colon cancer screening test Cologuard, according to a Milwaukee Journal Sentinel report.

Exact Sciences stock closed at $36.47 Wednesday, up $3.82. The company's shares have increased 449 percent during the past year.

The company's completed test volume also grew year-over-year by 150 percent, according to the report. 

More articles on supply chain:
Amgen sues FDA over drug exclusivity rights: 5 things to know
Appellate court: Fairvew Health's medical device telemarketing does not violate robocall rules 
Drug execs anticipate Trump's drug pricing plans: 4 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers